Literature DB >> 32030808

Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.

Qilong Tan1, Yue Huang1, Kui Deng1, Mingliang Lu1, Liuying Wang1, Zhiwei Rong1, Weiwei Zhao1, Shuang Li1, Zhenyi Xu1, Lijun Fan2, Kang Li1, Zhenzi Li1.   

Abstract

The tumor immune microenvironment is heterogeneous, and its impact on treatment responses is not well understood. It is still a challenge to analyze the interaction between malignant cells and the tumor microenvironment to apply suitable immunotherapy in lung adenocarcinoma. We performed the nonnegative matrix factorization method to 513 messenger RNA expression profiles of lung adenocarcinomas (LUADs) from The Cancer Genome Atlas (TCGA) to obtain an immune-related expression pattern. Subsequently, we characterized the immune-related gene signatures and clinical and survival characteristics. We used 576 patients from Gene Expression Omnibus to confirm our findings. Of the patients in the training cohort, 51% had a high immune enrichment score, high expression of immune cell signaling, cytolytic activity, and interferon (IFN)-related signatures (all P < .05). We denoted these as the Immune Class. We further subdivided the Immune Class into two subclasses based on the tumor microenvironment. These were denoted the Active Immune Class and Exhausted Immune Class. The former showed significant IFN, T-cells, M1 macrophage signatures, and better prognosis (all P < .05), while the latter presented an exhausted immune response with activated stromal enrichment, M2 macrophage signatures, and immunosuppressive factors such as WNT/transforming growth factor-β (all P < .05). Furthermore, we predicted the response of our immunophenotypes to immunological checkpoint inhibitors (P < .05). Our findings provide a novel insight into the immune-related state of LUAD and can identify the patients who will be receptive to suitable immunotherapeutic treatments.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  immune checkpoint blockade; immunophenotype; lung adenocarcinoma; tumor immune microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32030808     DOI: 10.1002/jcb.29675

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer.

Authors:  Hai Chen; Xianquan Xu; Tengfei Ge; Congshu Hua; Xiaodong Zhu; Qikui Wang; Zaicheng Yu; Renquan Zhang
Journal:  Int J Gen Med       Date:  2021-09-16

2.  Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis.

Authors:  Xueping Jiang; Yanping Gao; Nannan Zhang; Cheng Yuan; Yuan Luo; Wenjie Sun; Jianguo Zhang; Jiangbo Ren; Yan Gong; Conghua Xie
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

3.  Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses.

Authors:  Donglai Chen; Yifei Wang; Xi Zhang; Qifeng Ding; Xiaofan Wang; Yuhang Xue; Wei Wang; Yiming Mao; Chang Chen; Yongbing Chen
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

4.  A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma.

Authors:  Qianli Ma; Yang Chen; Fei Xiao; Yang Hao; Zhiyi Song; Jin Zhang; Katsuhiro Okuda; Sang-Won Um; Mario Silva; Yoshihisa Shimada; Chaozeng Si; Chaoyang Liang
Journal:  Transl Lung Cancer Res       Date:  2021-03

5.  Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy.

Authors:  Xiaobo Zheng; Yong Gao; Chune Yu; Guiquan Fan; Pengwu Li; Ming Zhang; Jing Yu; Mingqing Xu
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

6.  A Novel Intercellular Communication-Associated Gene Signature for Prognostic Prediction and Clinical Value in Patients With Lung Adenocarcinoma.

Authors:  Qin-Yu Zhao; Le-Ping Liu; Lu Lu; Rong Gui; Yan-Wei Luo
Journal:  Front Genet       Date:  2021-08-23       Impact factor: 4.599

7.  Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13.

Authors:  Jiangtao Wang; Weiwei Shi; Yandong Miao; Jian Gan; Quanlin Guan; Juntao Ran
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 8.  [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].

Authors:  Yichu Lin; Donglai Chen; Qifeng Ding; Xuejuan Zhu; Rongying Zhu; Yongbing Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.